HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Despite promising new regimens, search for cure is ‘highest priority’ in advanced renal cell carcinoma
-
- Does cytoreductive nephrectomy remain an essential component of care for advanced renal cell carcinoma?
- ASCO Annual Meeting: I got plenary of nothing! Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- Understanding affected anatomy, physiology essential to management of taste disorders David L. Jennings II, MSN, RN, AGPCNP-BC
- CDC opioid-prescribing guidelines impede patients who ‘should not have to fight for access’
- Combination therapy shows potential in TP53-mutated head and neck cancers
- Pediatric tumor-sequencing trial finds higher rate of targetable alterations than expected
- Entrectinib induces ‘rapid and durable’ responses in pediatric tumors with gene fusions
- Lower-dose chemotherapy benefits older, frail patients with advanced gastroesophageal cancer
-
- High-intensity bridging therapy before CAR T-cell infusion does not improve outcomes in leukemia subset
- Lenalidomide delays progression of smoldering myeloma
- Tumor-infiltrating lymphocyte therapy appears safe, effective in melanoma, cervical cancer
- Addition of apalutamide to ADT extends survival in metastatic castration-sensitive prostate cancer
- Excess body weight earlier in life may have greater influence on pancreatic cancer mortality risk
- Apalutamide-based triplet shows promise for metastatic castration-resistant prostate cancer
- Immunotherapy likely to become standard for recurrent/metastatic head and neck cancers
- Patients with head and neck cancer may be at risk for opioid misuse
-
- Lymphadenectomy fails to extend survival, linked to more complications in ovarian cancer
- Degarelix quickly induces ovarian function suppression in neoadjuvant breast cancer regimen
- Detection of JAK2 V617F mutations linked to myeloproliferative neoplasms
- FDA expands Kadcyla approval for adjuvant breast cancer therapy
- FDA grants orphan drug designation to APL-2 for autoimmune hemolytic anemia
- FDA grants fast track designation to annamycin for relapsed/refractory acute myeloid leukemia
- Fox Chase Cancer Center announces appointments
- Mount Sinai thoracic surgeon receives award
-
- UC Davis Comprehensive Cancer Center names physician-in-chief
- City of Hope provost admitted into Association of American Physicians